Entrada Therapeutics (TRDA) Change in Account Payables (2020 - 2026)

Entrada Therapeutics' Change in Account Payables history runs 7 years deep, the most recent figure standing at $641000.0 for Q1 2026.

• In Q1 2026, Change in Account Payables rose 133.56% year-over-year to $641000.0; the TTM figure through Mar 2026 stood at $752000.0 (up 384.85% YoY), while the FY2025 annual figure was -$1.8 million, down 281.53% from the prior year.
• Change in Account Payables was $641000.0 for Q1 2026 at Entrada Therapeutics, up from -$877000.0 in the prior quarter.
• In the past five years, Change in Account Payables ranged from a high of $4.6 million in Q4 2022 to a low of -$4.4 million in Q2 2023.
• Historically, Change in Account Payables has averaged $136176.5 across 5 years, with a median of -$314000.0 in 2024.
• Biggest YoY gain for Change in Account Payables was 869.03% in 2022; the steepest drop was 3733.75% in 2022.
• A 5-year view of Change in Account Payables shows it stood at $4.6 million in 2022, then plunged by 47.62% to $2.4 million in 2023, then advanced by 18.29% to $2.8 million in 2024, then plunged by 130.82% to -$877000.0 in 2025, then soared by 173.09% to $641000.0 in 2026.
• The last three Change in Account Payables figures came in at $641000.0 (Q1 2026), -$877000.0 (Q4 2025), and $1.3 million (Q3 2025), per Business Quant data.